SYMBOL:

    Up to 100 tickers separated by a space
Site Map FAQ Contact us Home Personalize
Company
Industry
Earnings
US Markets
Most Active
Portfolio
Tools
ETFs
Ratings
BIOHEART INC
(NQPK:BHRT Last Sale: .0109 )
Fundamentals Charts Tech Analysis Industry Earnings
Company Profile   Details

Company Web Site
NQPK: (BHRT : $.0109)
$2 million Market Cap at September 12, 2013
Biomedics SubIndustry up .00% / Health Industry up .00% Today
13794 NW 4th Street Research Report Earnings Snapshot - Last 11/14/15
Sunrise, FL 33325 Fact Sheet
Phone: 954-835-1500 Financial Statements
Peer Comparison
Annual Reports

Howard J. Leonhardt, CEO, William H. Kline, CFO
July 7, 2009 offering raised $2,855,830. Transfer to OTCBB February 26, 2009. Lead product candidate, MyoCell(r), is a clinical muscle-derived stem cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. Has multiple product candidates for the treatment of heart damage, including Bioheart Acute Cell Therapy, an autologous, adipose tissue-derived stem cell treatment for acute heart damage, and MyoCell(r) SDF-1, a therapy utilizing autologous cells that are genetically modified to express additional potentially therapeutic growth proteins. IPO at $5.25 February 18, 2008. Raised $5.8 million, selling 1.1 million shares, 8% of the outstanding. Lead Manager: Dawson James Securities, Inc.
Historical Charts    Technical Analysis
No Historical Data available for BHRT

Type of Stock Symbol Last Sale Last Close Net +/- % +/- Low High Volume 52wk Low 52wk High Shares(M)
Common BHRT $.0109 $ 0 $.0103 $.015 3,342,947 $.005 $.0565 151,375
Capitalization
Earnings Summary ()
*** No Earnings Available***
-10121
Common Stock $1,650

A
Google



QUICK NAVIGATION SITE SEARCH   Enter Keyword:
   
Home    Subscribe    Browser Help    Subscriber Services    B-to-B    Banks    Brokerage    Telco    Site Map    Legal    Contact/Email
Copyright © 1996 - 2024 Stock Smart with all rights reserved
Feed is currently being brought back up
Provided by Nanex